Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Summary

The study aims to test if combination of quizartinib (AC220) and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).

Timeline

Start

2017-10-01

Primary completion

2020-10-01

Completion

2021-10-01

Drugs

Indications